Home/ Stocks/ DNTH

Dianthus Therapeutics, Inc. Common Stock

DNTH XNAS

$108.92 -1.00 (-0.91%) ▼ 15-min delayed

Open

$111.60

High

$113.35

Low

$106.88

Volume

570.5K

Market Cap

$6.15B

About Dianthus Therapeutics, Inc. Common Stock

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 92 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$761.0K	$-50,215,000	$-0.90
Q1 2026	$463.0K	$-40,834,000	$-0.85
FY 2025	$2.04M	$-162,337,000	$-4.20
Q3 2025	$396.0K	$-36,765,000	$-0.97

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for DNTH yet. Check out our latest market news or earnings calendar.

Get DNTH Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Dianthus Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.